“We are thrilled to reach this crucial milestone in our clinical program”, said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The results of this Phase 2b study show promising reductions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results